Central Nervous System Complications of Oncologic Therapy

被引:9
作者
Hoeffner, Ellen G. [1 ]
机构
[1] Univ Michigan, Univ Hosp, Dept Radiol, UH-B2 A209,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA
关键词
Neurotoxicity; Chemotherapy; Radiation therapy; Magnetic resonance imaging; Cancer; REVERSIBLE ENCEPHALOPATHY SYNDROME; ACUTE LYMPHOBLASTIC-LEUKEMIA; RESONANCE-IMAGING FINDINGS; ENDOTHELIAL GROWTH-FACTOR; INDUCED BRAIN-TUMORS; HIGH-GRADE GLIOMA; RADIATION-INJURY; INTRATHECAL CHEMOTHERAPY; CEREBROVASCULAR COMPLICATIONS; CLINICAL-FEATURES;
D O I
10.1016/j.hoc.2016.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Traditional and newer agents used to treat cancer can cause significant toxicity to the central nervous system. MRI of the brain and spine is the imaging modality of choice for patients with cancer who develop neurologic symptoms. It is important to be aware of the agents that can cause neurotoxicity and their associated imaging findings so that patients are properly diagnosed and treated. In some instances, conventional MRI may not be able to differentiate posttreatment effects from disease progression. In these instances advanced imaging techniques may be helpful, although further research is still needed.
引用
收藏
页码:899 / +
页数:23
相关论文
共 94 条
[1]   Distinguishing Recurrent Primary Brain Tumor from Radiation Injury: A Preliminary Study Using a Susceptibility-Weighted MR Imaging-Guided Apparent Diffusion Coefficient Analysis Strategy [J].
Al Sayyari, A. ;
Buckley, R. ;
McHenery, C. ;
Pannek, K. ;
Coulthard, A. ;
Rose, S. .
AMERICAN JOURNAL OF NEURORADIOLOGY, 2010, 31 (06) :1049-1054
[2]   Imaging Findings in Cancer Therapy-Associated Neurotoxicity [J].
Arrillaga-Romany, Isabel C. ;
Dietrich, Jorg .
SEMINARS IN NEUROLOGY, 2012, 32 (04) :476-486
[3]  
Asao C, 2005, AM J NEURORADIOL, V26, P1455
[4]   CYTARABINE AND NEUROLOGIC TOXICITY [J].
BAKER, WJ ;
ROYER, GL ;
WEISS, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :679-693
[5]   Posterior reversible encephalopathy syndrome, part 1: Fundamental imaging and clinical features [J].
Bartynski, W. S. .
AMERICAN JOURNAL OF NEURORADIOLOGY, 2008, 29 (06) :1036-1042
[6]   Posterior reversible encephalopathy syndrome, part 2: Controversies surrounding pathophysiology of vasogenic edema [J].
Bartynski, W. S. .
AMERICAN JOURNAL OF NEURORADIOLOGY, 2008, 29 (06) :1043-1049
[7]   MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients [J].
Brandes, Alba A. ;
Franceschi, Enrico ;
Tosoni, Alicia ;
Blatt, Valeria ;
Pession, Annalisa ;
Tallini, Giovanni ;
Bertorelle, Roberta ;
Bartolini, Stefania ;
Calbucci, Fabio ;
Andreoli, Alvaro ;
Frezza, Giampiero ;
Leonardi, Marco ;
Spagnolli, Federica ;
Ermani, Mario .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2192-2197
[8]   Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas [J].
Brandsma, Dieto ;
Stalpers, Lukas ;
Taal, Walter ;
Sminia, Peter ;
van den Bent, Martinj .
LANCET ONCOLOGY, 2008, 9 (05) :453-461
[9]   What is the risk of intracranial bleeding during anti-VEGF therapy? [J].
Carden, Craig P. ;
Larkin, James M. G. ;
Rosenthal, Mark A. .
NEURO-ONCOLOGY, 2008, 10 (04) :624-630
[10]   Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma [J].
Chamberlain, Marc C. ;
Glantz, Michael J. ;
Chalmers, Lisa ;
Van Horn, Alixis ;
Sloan, Andrew E. .
JOURNAL OF NEURO-ONCOLOGY, 2007, 82 (01) :81-83